



## **ABFERO ANNOUNCES FUNDING FROM KYTO TECHNOLOGY AND LIFE SCIENCE, INC.**

***Funding follows recently announced trial in transfusion related iron overload***

Boston, MA (May 20, 2021) – [AbFero Pharmaceuticals, Inc.](#), a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the addition of a new investor, [KYTO Technology and Life Science, Inc.](#) The Los Altos Hills based firm is a public specialized investor in early stage technology and life science companies, and it joins [UF Innovate I Ventures](#), [DeepWork Capital](#), and lead investor [Longwall Ventures](#).

“We are pleased to expand our roster of investors with KYTO, who share our vision of the important role of iron across a variety of serious conditions,” said AbFero Founder and CEO [Thomas X. Neenan, Ph.D.](#) “With the initiation of our recently announced trial in transfusion related iron overload, we continue to make progress in reaching our goal of developing best-in-class, next generation chelators. The addition of another focused and specialized investor like KYTO propels us closer to that goal.”

“KYTO is delighted to participate in this critical AbFero Pharmaceuticals financing to help advance unique solutions to the multiple diseases and medical conditions impacted by iron overload. We are happy to become long-term partners in this exciting endeavor,” said KYTO Chairman and CEO Paul Russo, PhD.

“Emerging data continues to suggest iron accumulation plays a key role in neurodegenerative diseases and conditions and diseases of aging,” Neenan notes. “AbFero has a particular interest in the role of iron in those diseases – specifically Parkinson’s, Alzheimer’s, macular degeneration and myelodysplastic syndrome – which are rising along with the growth of the aging population. Our novel, brain-penetrant, small molecule chelator platform may prove to be an important addition to existing therapies.”

### **About AbFero**

AbFero Pharmaceuticals is a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload. AbFero’s technology is based upon the discoveries of a pioneer in the field of iron chelator medicinal chemistry, Professor Raymond Bergeron, University of Florida. Our therapeutic platform addresses transfusional iron overload (TIO) and iron accumulation associated with diseases of aging such as age-related macular degeneration (AMD) and Parkinson’s disease. AbFero has completed three clinical trials with the company’s lead iron chelator, SP-420. AbFero Pharmaceuticals, Inc., is based in Boston, Massachusetts, and our subsidiary, AbFero, Ltd., is located in Harwell, UK. For more information, visit: <https://www.abferopharmaceuticals.com>.

### **Investor & Media Contact:**

Mih-Ho Cha

[mcha@abfero.com](mailto:mcha@abfero.com)

